BSD Reports Increasing European Market Penetration by Terumo for MicroThermX® Microwave Ablation System

  BSD Reports Increasing European Market Penetration by Terumo for
  MicroThermX® Microwave Ablation System

Business Wire

SALT LAKE CITY -- October 24, 2013

BSD Medical Corporation (NASDAQ: BSDM) (“Company” or “BSD”) today reported
that Terumo Europe NV (Terumo), a wholly owned subsidiary of Terumo
Corporation, has already introduced the MicroThermX^® Microwave Ablation
System (MicroThermX) into the major markets in Europe, including Germany,
France and Spain.

Terumo has performed numerous clinical procedures throughout Europe, which has
led to enhanced clinical acceptance and greater market penetration. The market
potential in the 100 countries included in the Terumo contract is in excess of
$1 billion in annual sales. As a result of the increased clinical acceptance,
Terumo continues to increase their purchases of MicroThermX generators and
antennas.

"Terumo has made a substantial investment in commercialization of the
MicroThermX, and their market penetration has already exceeded our
expectations. There is a critical need for innovative, cost-effective cancer
treatment technologies throughout the world due to the increasing cost of
health care," said Sam Maravich, Vice President of Sales and Marketing for
BSD. "The MicroThermX system is innovative and cost-effective. Our technology
allows the clinician to treat multiple types and sizes of tumors with one
minimally invasive system, which significantly reduces procedure cost and
complexity. The healthcare systems in the majority of European countries are
structured to facilitate fast adoption of minimally invasive, efficacious,
cost-effective, advanced technology like the MicroThermX."

About Terumo Corporation

A world leader in state-of-the-art medical devices and interventional
oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2013 sales of
nearly $5 billion and has a market cap in excess of $8 billion. Through the
sale and promotion of a high quality line of devices used for tumor
embolization, the closing or blocking of blood vessels, Terumo Europe NV has
established itself as a pioneer in the field of interventional oncology.

About the MicroThermX^® Microwave Ablation System

The MicroThermX is a compact, mobile, state-of-the-art, proprietary system
that includes a microwave generator, single-patient-use disposable antennas,
and a thermistor-based temperature monitoring system. The innovative design of
the MicroThermX is the first of its kind that allows delivery of higher power
levels using a single generator. The MicroThermX utilizes innovative
synchronous phased array technology that was developed and patented by BSD to
provide a wide range of uniform zones of ablation. The MicroThermX includes
innovative, high-end disposables (SynchroWave antennas) that are used in each
ablation treatment and will provide a significant ongoing revenue stream. The
soft tissue (tumor) ablation world market potential is estimated to exceed
$2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the
Company a 510(k) clearance to market the MicroThermX for ablation of soft
tissue. BSD has also received CE Marking for the MicroThermX System, which
allows BSD to market the MicroThermX in Europe. CE Marking is also recognized
in many countries outside of the EU, providing BSD the ability to market the
MicroThermX to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

BSD Medical Corporation
William Barth, 801-972-5555
investor@bsdmc.com
fax: 801-972-5930
 
Press spacebar to pause and continue. Press esc to stop.